Redx Pharma (LON:REDX) Stock Passes Below 50 Day Moving Average – Here’s Why

Redx Pharma Plc (LON:REDX)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 15 ($0.20) and traded as low as GBX 11.42 ($0.15). Redx Pharma shares last traded at GBX 15 ($0.20), with a volume of 1,420,135 shares trading hands.

Redx Pharma Stock Up 31.6 %

The stock has a market cap of £58.35 million, a PE ratio of -150.00 and a beta of -0.53. The business has a fifty day moving average of GBX 15 and a 200-day moving average of GBX 14.83. The company has a debt-to-equity ratio of 527.00, a current ratio of 1.11 and a quick ratio of 1.93.

Redx Pharma Company Profile

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.